An interventional study of Yingtong Vision Rehabilitation Instrument and Hoya DIMS multi-point myopia defocus lens in Myopia and Myopia, Progressive, sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Not yet recruiting at 7 sites in China. Open to participants aged 6 Years to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-09.
Sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 222 studies in Myopia with a site in China — 80 open to participants now, 102 under way, 4 of them phase 3. Myopia · China.
Among the 222 studies in Myopia with a site in China, this one is the 30th largest by planned enrollment of the 155 interventional ones that give a count, is one of 24 that started in 2026, is one of 136 with no phase, reaches primary completion later than 64 of the 101 other live ones, and was the 191st registered.
1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →80 of the 222 studies in Myopia with a site in China are open now. Recruiting first, the newest first:
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 3–6
Beijing Tongren Hospital · Sites in China
Healthy volunteers
Zhongshan Ophthalmic Center, Sun Yat-sen University · Sites in China
Ages 6–18 · Healthy volunteers
CooperVision International Limited (CVIL) · Sites in China
Ages 8–10
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 6–11 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.
This study: 6 Years to 14 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
222 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 8 · Phase 4 7
First in 2005; this study’s year is marked. 24 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 364 is above the median of 79 across 929 interventional studies indexed under Myopia.
Median enrollment 150 across the 155 interventional studies, 1,000 across the 67 observational. Of the 77 that completed or were terminated, 5 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 222 have an industry lead sponsor. The 10 most frequent:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine is the lead sponsor of 182 studies on the registry; 108 are open to participants now.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine has 1 study filed under Myopia — fewer than ten, so there is no comparison to draw.
35 of the studies in Myopia with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06708156Phase 3Oupushifang Pharmaceutical Technology Co., Ltd.The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression | 2026-12-31 |
| NCT07585877Zhongda HospitalEffect of Branched-Chain Amino Acid Supplementation on Myopia Progression | 2026-12-30 |
| NCT07119723Tianjin Medical University Eye HospitalEnvironmental Factors and Myopia Prevalence Among Uyghur Students in Remote China | 2026-12-30 |
| NCT07008001SightGlass Vision, Inc.Assessment of DOT Spectacles in Chinese Children Extension | 2026-12-31 |
| NCT06667037Zhongshan Ophthalmic Center, Sun Yat-sen UniversityOrthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control | 2026-12-31 |
Add all 35 to your calendar (.ics) → With an account.
Among the 222 studies in Myopia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to verify the effectiveness and safety of non-laser LED red light combined with defocus lens therapy for controlling myopia progression and evaluate the impact of different intervention durations in 6-14 years old children and adolescents with myopia (spherical equivalent refraction: -6.00D ≤ SER ≤ -1.00D), regardless of gender. The main questions it aims to answer are:
[primary hypothesis or outcome measure 1]: Does the combination of Yingtong Vision Rehabilitation Instrument (non-laser LED red light) and Hoya DIMS defocus lens show non-inferior effectiveness to Hoya DIMS defocus lens alone in controlling 6-month axial length change? [primary hypothesis or outcome measure 2]: Do different single intervention durations (2min, 3min, 4min) of non-laser LED red light affect the effectiveness (e.g., axial length change at multiple time points, 12-month SER change) and safety of the combined therapy? If there is a comparison group: Researchers will compare Test Group A (2min PBM therapy + DIMS lenses), Test Group B (3min PBM therapy + DIMS lenses), Test Group C (4min PBM therapy + DIMS lenses), and Control Group D (DIMS lenses alone)] to see if the combined therapy has similar or better myopia control effects and comparable safety, and to identify the optimal intervention duration.
Participants will:
Complete screening examinations (axial length, refractive error, visual acuity, IOP, fundus photography, OCT, etc.) and sign the informed consent form.
Be randomly assigned to one of the four groups and receive the corresponding intervention (use the Yingtong Vision Rehabilitation Instrument as per group-specific duration twice a day, with ≥4-hour interval, plus DIMS lenses; or only DIMS lenses).
Attend regular follow-up visits at 30 days, 3 months, 6 months, 9 months, and 12 months for efficacy and safety assessments (including repeated ocular examinations and adverse event reporting).
Cooperate with the entire 12-month trial process and comply with the device usage specifications and follow-up requirements.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PBM therapy with single intervention duration of 2 minutes + wearing Hoya DIMS defocus lens
Device: Yingtong Vision Rehabilitation Instrument · Device: Hoya DIMS multi-point myopia defocus lens
PBM therapy with single intervention duration of 3 minutes + wearing Hoya DIMS defocus lens
Device: Yingtong Vision Rehabilitation Instrument · Device: Hoya DIMS multi-point myopia defocus lens
PBM therapy with single intervention duration of 4 minutes + wearing Hoya DIMS defocus lens
Device: Yingtong Vision Rehabilitation Instrument · Device: Hoya DIMS multi-point myopia defocus lens
Wearing Hoya DIMS defocus lens only
Device: Hoya DIMS multi-point myopia defocus lens
Input voltage: 6V (4 × 1.5V alkaline dry batteries). Red light wavelength: 650nm; light spot diameter: outer diameter 5.0mm, inner diameter 1.5mm. Light source output power: 1.6 mW (±0.1mW at 30mm from the observation window). The Yingtong Vision Rehabilitation Instrument should be used twice a day under the regular communication and supervision of hospital optometrists/coordinators (via phone, WeChat, etc.), with an interval of at least 4 hours.
Frame glasses worn on the bridge of the nose
6-month axial length change
The difference in axial length at 6 months after trial initiation compared with the baseline axial length
Time frame: 6-month
1-, 3-, 9- and 12-month axial length changes
The difference in axial length at 1-, 3-, 9- and 12-month after trial initiation compared with the baseline axial length
Time frame: 1-, 3-, 9- and 12-month
12-month spherical equivalent refraction (SER) change
The difference in spherical equivalent refraction at 12-month after trial initiation compared with the baseline spherical equivalent refraction
Time frame: 12-month
Adverse event rate and serious adverse event rate
Adverse event rate and serious adverse event rate
Time frame: 1-, 3-, 6-, 9- and 12-month
12-month visual adverse event rate
BVCA decrease ≥0.2 logMAR
Time frame: 12-month
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Start is estimated for Jan 2026; primary completion for Apr 2027, 15 months later.
Of 202 non-industry interventional studies with no phase under Myopia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 15 months is below that.
Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine →